Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its revenue primarily comes from instruments (40-50%), consumables (30-40%), and services (10-20%) related to genetic analysis. Customers include genomic research centers, academic institutions, government laboratories, hospitals, and companies in pharmaceuticals and biotechnology. Factors supporting endurance include a growing demand for genomic solutions in various fields and a strong position in the market. However, competition and potential regulatory changes could limit growth.
—
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its revenue primarily comes from instruments (40-50%), consumables (30-40%), and services (10-20%) related to genetic analysis. Customers include genomic research centers, academic institutions, government laboratories, hospitals, and companies in pharmaceuticals and biotechnology. Factors supporting endurance include a growing demand for genomic solutions in various fields and a strong position in the market. However, competition and potential regulatory changes could limit growth.
—
Daily adjusted close
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its revenue primarily comes from instruments (40-50%), consumables (30-40%), and services (10-20%) related to genetic analysis. Customers include genomic research centers, academic institutions, government laboratories, hospitals, and companies in pharmaceuticals and biotechnology. Factors supporting endurance include a growing demand for genomic solutions in various fields and a strong position in the market. However, competition and potential regulatory changes could limit growth.